PPARgamma agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone.
about
sameAs
Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factorsLiver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes.Beta-cell preservation: a potential role for thiazolidinediones to improve clinical care in Type 2 diabetes.Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.Identification of a proliferator-activated receptor-γ antagonist for the treatment of type 2 diabetes mellitus.Anti-diabetic activity of swertiamarin is due to an active metabolite, gentianine, that upregulates PPAR-γ gene expression in 3T3-L1 cells.Insulin sensitivity at diagnosis of Type 2 diabetes is not associated with subsequent cardiovascular disease (UKPDS 67).Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study.
P2860
Q34133889-692940EC-D345-4EB0-9021-4925391AB88BQ34835012-CC4D7F40-9AE4-40BB-9A11-75F5090FB865Q36198965-FDA7240F-6644-4713-AD4F-12279BB18C29Q36390892-E9CC954C-997D-4E89-99F9-C4AF7782BECCQ42036117-A2AA86F4-AD3D-4042-933B-F8703F7F2DFBQ42833565-C2C058A4-0BDB-4414-8357-28DB91522496Q45271283-4E779F6E-30E1-474D-B4B2-953D955503A8Q46963140-1F169247-6F2B-4A5A-BCBD-458083281886
P2860
PPARgamma agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone.
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
PPARgamma agonists in type 2 d ...... olic effects of rosiglitazone.
@ast
PPARgamma agonists in type 2 d ...... olic effects of rosiglitazone.
@en
PPARgamma agonists in type 2 d ...... olic effects of rosiglitazone.
@nl
type
label
PPARgamma agonists in type 2 d ...... olic effects of rosiglitazone.
@ast
PPARgamma agonists in type 2 d ...... olic effects of rosiglitazone.
@en
PPARgamma agonists in type 2 d ...... olic effects of rosiglitazone.
@nl
altLabel
PPAR gamma agonists in type 2 ...... olic effects of rosiglitazone.
@ast
PPAR gamma agonists in type 2 ...... olic effects of rosiglitazone.
@en
PPAR gamma agonists in type 2 ...... olic effects of rosiglitazone.
@nl
prefLabel
PPARgamma agonists in type 2 d ...... olic effects of rosiglitazone.
@ast
PPARgamma agonists in type 2 d ...... olic effects of rosiglitazone.
@en
PPARgamma agonists in type 2 d ...... olic effects of rosiglitazone.
@nl
P2860
P1476
PPAR gamma agonists in type 2 ...... olic effects of rosiglitazone.
@en
PPARgamma agonists in type 2 d ...... olic effects of rosiglitazone.
@en
P2093
Bernard Zinman
P2860
P356
10.1046/J.1463-1326.2001.00033.X
P478
P577
2001-08-01T00:00:00Z